封面
市場調查報告書
商品編碼
1593532

小分子 API 市場規模、佔有率和成長分析(按類型、製造商、應用、地區):產業預測 (2024-2031)

Small Molecule API Market Size, Share, Growth Analysis, By Type (Synthetic, Biotech), By Manufacturer (In-house, Outsourced), By Application (Cardiology, Oncology), By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 172 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球小分子API(小分子原料藥)市場規模為1848.5億美元,從2023年的1949億美元擴大到2031年的2977.6億美元,預計將以複合年成長率成長。將成長5.44%。

在慢性病盛行率上升以及藥物發現和開發投資增加的推動下,全球小分子活性藥物原料藥(API)格局預計將顯著成長。品牌藥價格的飆升正在刺激學名藥的轉移,預計未來小分子原料藥的需求將進一步增加。此外,API 合成技術的進步和小分子研究投資的增加正在為 API 供應商創造新的機會。對負擔得起的癌症藥物的需求不斷成長預計也將刺激全球範圍內的市場擴張。然而,製造流程複雜、製造成本高和嚴格的法律規範等挑戰可能會阻礙未來的市場需求。儘管如此,對永續和連續製造實踐的日益關注為公司在不斷變化的市場環境中創新和取得成功提供了潛在的途徑。這些因素的綜合顯示小分子原料藥產業的未來充滿活力,並強調需要進行策略調整,以利用新出現的機遇,同時克服固有的挑戰。

目錄

介紹

  • 研究目的
  • 定義
  • 市場範圍

調查方法

  • 資訊採購
  • 二手資料來源和主要資料來源
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 市場概況展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 波特的分析

主要市場考察

  • 關鍵成功因素
  • 競爭程度
  • 主要投資機會
  • 市場生態系統
  • 母市場分析
  • PESTEL分析
  • 監管環境

小分子 API 市場:按類型

  • 市場概況
  • 合成
  • 生物技術

小分子 API 市場:依製造商分類

  • 市場概況
  • 公司內部
  • 外包

小分子 API 市場:依應用分類

  • 市場概況
  • 心臟病學
  • 腫瘤學
  • 中樞神經系統/神經病學
  • 整形外科
  • 內分泌學
  • 呼吸系統醫療設備
  • 胃腸病學
  • 腎臟病學
  • 眼科
  • 其他

小分子 API 市場:按地區

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲 (MEA)
    • 波灣合作理事會(GCC) 國家
    • 南非
    • 其他中東/非洲

競爭格局

  • 前5名企業對比
  • 主要企業市場定位(2023年)
  • 主要市場參與者所採取的策略
  • 近期市集活動
  • 主要企業市場佔有率(2023年)

主要企業簡介

  • 莊信萬豐(英國)
  • 輝瑞公司(美國)
  • 南京金友生化製藥有限公司 (中國)
  • 賽諾菲公司(法國)
  • 諾華公司(瑞士)
  • 百時美施貴寶(美國)
  • 勃林格殷格翰有限公司(德國)
  • 葛蘭素史克公司(英國)
  • 吉利德科學公司(美國)
  • 奧爾巴尼分子研究公司(美國)
  • 阿斯特捷利康(英國)
  • 默克公司(美國)
  • BASF公司(德國)
  • 梯瓦製藥(以色列)
  • 霍夫曼拉羅氏有限公司(瑞士)
  • 雅寶公司(美國)
  • 艾伯維(美國)
  • Aurobindo Pharma(印度)
  • Cambrex 公司(美國)
  • 雷迪博士實驗室有限公司(印度)
  • 龍沙(瑞士)
  • 默克公司(德國)
  • 齊格飛控股公司(瑞士)
  • 太陽製藥工業有限公司(印度)
簡介目錄
Product Code: SQMIG35I2356

Global Small Molecule API Market size was valued at USD 184.85 billion in 2022 and is poised to grow from USD 194.90 billion in 2023 to USD 297.76 billion by 2031, growing at a CAGR of 5.44% in the forecast period (2024-2031).

The global landscape for small molecule active pharmaceutical ingredients (APIs) is poised for significant growth, driven by the rising prevalence of chronic diseases and increased investments in drug discovery and development. The soaring prices of branded medications are fueling a shift towards generic drugs, which is anticipated to further enhance the demand for small molecule APIs in the coming years. Additionally, advancements in API synthesis technologies and heightened investment in small molecule research present new opportunities for API suppliers. The escalating need for affordable oncology medications is also expected to stimulate market expansion on a worldwide scale. However, challenges such as the complexity of manufacturing processes, high production costs, and stringent regulatory frameworks may hinder market demand moving forward. Nonetheless, a growing focus on sustainable and continuous manufacturing methodologies offers potential avenues for small molecule API companies to innovate and thrive in the evolving market landscape. This convergence of factors signals a dynamic future for the small molecule API sector, emphasizing the need for strategic adaptations to leverage emerging opportunities while navigating inherent challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Small Molecule Api market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Small Molecule Api Market Segmental Analysis

Global Small Molecule API Market is segmented on the type, manufacturer, application, and region. By type, the market is segmented into Synthetic and Biotech. By manufacturer, the market is segmented into In-house and Outsourced. By application, the market is segmented into Cardiology, Oncology, CNS and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Small Molecule Api Market

The rising prevalence of chronic disorders attributable to poor lifestyle choices is a significant market driver for the Global Small Molecule API market. As an increasing number of individuals grapple with conditions such as diabetes, cardiovascular diseases, and obesity, the demand for effective pharmaceutical interventions continues to surge. This growing need for targeted therapies propels the production and utilization of small molecule active pharmaceutical ingredients (APIs), known for their efficacy in treating a wide range of ailments. Consequently, the sustained expansion of healthcare expenditures and a focus on innovative drug development strategies further reinforce the momentum of the small molecule API market globally.

Restraints in the Global Small Molecule Api Market

The Global Small Molecule API market faces significant restraints due to the high manufacturing costs associated with the production of small molecule APIs. The process necessitates specialized equipment and facilities, which demand substantial capital investment. Additionally, the requirement for skilled professionals to operate such equipment further escalates operational costs. The reliance on expensive raw materials compounds these financial burdens, ultimately limiting the ability of manufacturers to scale production competitively. This cost-intensive aspect not only hinders market entry for new players but also restricts expansion opportunities for existing companies, thereby stifling overall market growth and development potential.

Market Trends of the Global Small Molecule Api Market

The Global Small Molecule API market is increasingly influenced by the rise of personalized medicine, driving a significant market trend towards tailored therapeutic solutions. As healthcare transitions to individualized treatment plans, small molecule API providers are optimizing their business models to address specific patient needs and niche markets. This shift is facilitating the development of innovative small molecule APIs that target unique biomarkers and genetic profiles, promising substantial returns for industry players. Consequently, this trend not only enhances treatment efficacy but also positions companies to thrive in a competitive landscape, thereby shaping the future of the pharmaceutical industry.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Parent Market Analysis
  • PESTEL Analysis
  • Regulatory Landscape

Small Molecule API Market, By Type

  • Market Overview
  • Synthetic
  • Biotech

Small Molecule API Market, By Manufacturer

  • Market Overview
  • In-house
  • Outsourced

Small Molecule API Market, By Application

  • Market Overview
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others

Small Molecule API Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Johnson Matthey (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GILEAD Sciences Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albany Molecular Research Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co. Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BASF SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceuticals (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albemarle Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cambrex Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siegfried Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments